These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


138 related items for PubMed ID: 24524103

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Advances in pharmacotherapy for the treatment of allergic rhinitis; MP29-02 (a novel formulation of azelastine hydrochloride and fluticasone propionate in an advanced delivery system) fills the gaps.
    Bousquet J, Bachert C, Bernstein J, Canonica GW, Carr W, Dahl R, Demoly P, Devillier P, Hellings P, Fokkens W, Klimek L, Lieberman P, Meltzer E, Price D, Ryan D, Wahn U.
    Expert Opin Pharmacother; 2015 Apr; 16(6):913-28. PubMed ID: 25747125
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Escaping the trap of allergic rhinitis.
    Rossi O, Massaro I, Caminati M, Quecchia C, Fassio F, Heffler E, Canonica GW.
    Clin Mol Allergy; 2015 Apr; 13(1):17. PubMed ID: 26244040
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Bioavailability and disposition of azelastine and fluticasone propionate when delivered by MP29-02, a novel aqueous nasal spray.
    Derendorf H, Munzel U, Petzold U, Maus J, Mascher H, Hermann R, Bousquet J.
    Br J Clin Pharmacol; 2012 Jul; 74(1):125-33. PubMed ID: 22356350
    [Abstract] [Full Text] [Related]

  • 8. Clinically relevant effect of a new intranasal therapy (MP29-02) in allergic rhinitis assessed by responder analysis.
    Meltzer E, Ratner P, Bachert C, Carr W, Berger W, Canonica GW, Hadley J, Lieberman P, Hampel FC, Mullol J, Munzel U, Price D, Scadding G, Virchow JC, Wahn U, Murray R, Bousquet J.
    Int Arch Allergy Immunol; 2013 Jul; 161(4):369-77. PubMed ID: 23652808
    [Abstract] [Full Text] [Related]

  • 9. Long-term, randomized safety study of MP29-02 (a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate in an advanced delivery system) in subjects with chronic rhinitis.
    Berger WE, Shah S, Lieberman P, Hadley J, Price D, Munzel U, Bhatia S.
    J Allergy Clin Immunol Pract; 2014 Jul; 2(2):179-85. PubMed ID: 24607046
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Comparison of intranasal azelastine to intranasal fluticasone propionate for symptom control in moderate-to-severe seasonal allergic rhinitis.
    Carr WW, Ratner P, Munzel U, Murray R, Price D, Canonica GW, Mullol J, Virchow JC, Lieberman P, Meltzer E, Bachert C.
    Allergy Asthma Proc; 2012 Jul; 33(6):450-8. PubMed ID: 23127291
    [Abstract] [Full Text] [Related]

  • 14. Efficacy of a Novel Intranasal Formulation of Azelastine Hydrochloride and Fluticasone Propionate, Delivered in a Single Spray, for the Treatment of Seasonal Allergic Rhinitis: Results from Russia.
    Ilyina NI, Edin AS, Astafieva NG, Lopatin AS, Sidorenko IV, Ukhanova OP, Khanova FM.
    Int Arch Allergy Immunol; 2019 Jul; 178(3):255-263. PubMed ID: 30677766
    [Abstract] [Full Text] [Related]

  • 15. MP29-02 reduces nasal hyperreactivity and nasal mediators in patients with house dust mite-allergic rhinitis.
    Kortekaas Krohn I, Callebaut I, Alpizar YA, Steelant B, Van Gerven L, Skov PS, Kasran A, Talavera K, Wouters MM, Ceuppens JL, Seys SF, Hellings PW.
    Allergy; 2018 May; 73(5):1084-1093. PubMed ID: 29121401
    [Abstract] [Full Text] [Related]

  • 16. A review of the clinical efficacy and safety of MP-AzeFlu, a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate, in clinical studies conducted during different allergy seasons in the US.
    Prenner BM.
    J Asthma Allergy; 2016 May; 9():135-43. PubMed ID: 27468241
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Azelastine and fluticasone nasal spray: any advantage?
    Drug Ther Bull; 2014 Feb; 52(2):21-4. PubMed ID: 24504481
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Combination therapy with azelastine hydrochloride nasal spray and fluticasone propionate nasal spray in the treatment of patients with seasonal allergic rhinitis.
    Ratner PH, Hampel F, Van Bavel J, Amar NJ, Daftary P, Wheeler W, Sacks H.
    Ann Allergy Asthma Immunol; 2008 Jan; 100(1):74-81. PubMed ID: 18254486
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 7.